Interstitial inflammation and pulmonary fibrosis in COVID-19: The potential role of cytostatic therapy for severe lung injury
Open Access
- 27 May 2022
- journal article
- research article
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 38, 101676
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosisEuropean Respiratory Review, 2019
- Current and future perspectives on management of systemic sclerosis-associated interstitial lung diseaseExpert Review of Clinical Immunology, 2019
- Acute and subacute idiopathic interstitial pneumoniasRespirology, 2016
- Low dose cyclophosphamide: Mechanisms of T cell modulationCancer Treatment Reviews, 2016
- The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPFEuropean Respiratory Journal, 2015
- The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significanceEuropean Respiratory Journal, 2013
- Influenza A (H1N1) organising pneumonia: Figure 1BMJ Case Reports, 2010
- Alkylating drugs applied in non-cytotoxic doses as a novel compounds targeting inflammatory signal pathwayBiochemical Pharmacology, 2006
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002
- Effect of cytostatic agents on the number of alveolar phagocytes and the efficacy of ceftriaxone in an experimental murine lung infectionEuropean Respiratory Journal, 1991